Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clofarabine - Sanofi Genzyme

Drug Profile

Clofarabine - Sanofi Genzyme

Alternative Names: CAFdA; Cl-F-ara-A; Clofaribine; Clolar; Evoltra; GZ393590; JC0707; SAR 393590

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Southern Research Institute
  • Developer Bioenvision; Dana-Farber Cancer Institute; Erasmus MC; Genzyme Corporation; Genzyme Oncology; Massachusetts General Hospital; Oncology Specialists S.C.; Sanofi Genzyme; Sanofi Oncology; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospital Southampton NHS Foundation Trust; University of Michigan Comprehensive Cancer Center; University of Utah; Yale University
  • Class Antineoplastics; Furans; Purine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Histiocytosis
  • Phase I/II Haematological malignancies
  • Preregistration Submission Withdrawal Acute myeloid leukaemia
  • Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Psoriasis; Solid tumours

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(In children) in Unknown (PO)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater, In adults) in Canada (IV, Infusion)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top